Skip to content
NBlaz – Lifestyle
Author:
RIGEL PHARMACEUTICALS, INC.
Rigel Announces Publication of Final ARROW Clinical Trial Data on GAVRETO® (pralsetinib) in Patients with RET+ NSCLC in the Journal of Clinical Oncology
March 31, 2026
←
Previous Page
1
2